U

University of Massachusetts | Chan Medical School - Aaron Lazare Medical Research Building - Dermatology Department

Research site
(Unclaimed)
Location
364 Plantation Street, LRB 1002, Worcester, Massachusetts, United States of America
Site insights

Top conditions

Aneurysm (10 trials)

Stroke (6 trials)

Aortic Aneurysm (6 trials)

Schizophrenia (5 trials)

Iliac Aneurysm (5 trials)

Top treatments

Arbaclofen
STX209
Olanzapine
Litifilimab
Aripiprazole
Platinum
Gemcitabine
BIIB059
Metformin
Cilengitide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

23 of 98
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

This research study is studying a drug combination as a possible treatment for endometrial cancer.The drugs involved in this study are:mirvetuximab s...

Enrolling
Endometrial Cancer
Drug: IMGN853
Drug: Pembrolizumab

The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92...

Active, not recruiting
Acute Ischemic Stroke
Device: Route 92 Medical Reperfusion System

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients wit...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST...

Enrolling
Chemotherapy-induced Peripheral Neuropathy
Drug: WST-057 Active
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetax...

Enrolling
Prostate Cancer
Drug: Radium-223
Drug: Docetaxel 60 mg/m2

This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in a...

Active, not recruiting
Endometrial Cancer
Drug: Abemaciclib
Drug: Letrozole

To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects wi...

Enrolling
Aortic Stenosis
Device: ACURATE neo2™ Transfemoral TAVR System
Device: Edwards SAPIEN 3 TAVR System

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Enrolling
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling
Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in sub...

Active, not recruiting
Abdominal Aortic Aneurysm (AAA)
Device: Subjects who receive the Treovance stent-graft

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodyspl...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combina...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems undergo procedures that use iodinated contrast media, su...

Active, not recruiting
Contrast Induced Nephropathy
Drug: Standard Therapy
Device: RenalGuard Therapy

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resecti...

Enrolling
Colorectal Neoplasms
Drug: SGM-101

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly as...

Enrolling
Multiple Myeloma
Drug: GPC-100
Drug: G-CSF

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

Active, not recruiting
Amyotrophic Lateral Sclerosis
Drug: AMX0035
Other: Placebo

To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Active, not recruiting
Vitiligo
Device: RECELL® Autologous Cell Harvesting Device

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum r...

Active, not recruiting
Platinum-resistant Ovarian Cancer
Drug: Afuresertib
Drug: Paclitaxel

Trial sponsors

U

University of Massachusetts, Worcester (6 trials)

Celgene logo

Celgene (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems